Skin Irritation
13
0
0
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
15%
2 trials in Phase 3/4
10%
1 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (13)
HRIPT Study to Evaluate the Irritation and Allergenic Potential of Medical-grade Norway Spruce (Picea Abies) Resin Salve (Abilar)
Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
Patch Test Skin Irritation/Sensitization of Cetaphil Restoraderm Skin Restoring Body Wash
Patch Test Skin Irritation/Sensitization of Cetaphil Daily Facial Moisturizer SPF 50
Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Dermacontrol Oil Control Moisturizer SPF 30
Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Daily Facial Cleanser
Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion
Effect of Vitamin D After Application With Valchlor
A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System
Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol
Evaluation of Effectiveness and Mildness of Whole-natural Hand-wash Formulations
Efficacy and Safety of Biocellulose Sheet Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment
A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design